CASE REPORT: Giant Cell Tumour of Distal Left Tibia: A Case Report.

West Afr J Med. 2021 Jan; 38(1): 84-92. PMID: 33463713

Authors

  • F. S. Ejagwulu Department of Orthopaedics and Traumatology, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.
  • K. E. Amaefule Department of Orthopaedics and Traumatology, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.
  • I. L. Dahiru Department of Orthopaedics and Traumatology, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.
  • I. M. Maitama Department of Orthopaedics and Traumatology, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.
  • I. Aniko Department of Orthopaedics and Traumatology, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.
  • I. Zubairu Department of Orthopaedics and Traumatology, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.
  • E. E. Ejagwulu Department of Surgery, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.

Keywords:

Giant cell tumour, benign, Linear Rail System, distraction osteogenesis, adjuvants, aggressive, malignant, recurrence, radiation, embolization, chemotherapy

Abstract

Giant cell tumours of bone are relatively uncommon, accounting for about 5% of all primary bone tumours. They are generally classified as benign bone tumours. However, some of them might be locally aggressive. The peak incidence is between second and fourth decades of life. They are commonly found at the epiphyseal and, occasionally, metaphyseal zones of long bones such as radius, femur and tibia. They most often present as painless swellings; however, pain may be experienced as a result of pressure on the surrounding soft tissues. The relevant diagnostic investigations that help in establishing the diagnosis include plain x-rays, Magnetic resonance imaging (MRI), CT and tissue biopsy for histological confirmation. Traditionally, surgery is the mainstay of treatment of the disease. Other modalities include radiation, tumour embolization and injectable drugs for surgically inaccessible or recurrent cases.

Published

2021-01-31